Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical Inc (RMTI) delivers innovative therapies for chronic kidney disease and hemodialysis patients, including the only FDA-approved iron replacement therapy administered via dialysate. This page provides investors and healthcare professionals with centralized access to official press releases, clinical trial updates, and business developments directly impacting renal care innovation.
Track RMTI's progress in advancing dialysis solutions like triferic® and critical concentrates that maintain metabolic balance during treatment. Stay informed about regulatory milestones, partnership announcements, and research breakthroughs that shape the company's role in improving patient outcomes.
Key updates across three focus areas: iron deficiency management advancements, dialysis product innovations, and strategic initiatives enhancing renal care delivery. Bookmark this resource for verified information on RMTI's contributions to reducing treatment complications in ESRD patients.
Rockwell Medical (NASDAQ:RMTI) reported its Q2 2025 financial results, showing significant changes in its business landscape. The company generated $1.8 million in cash flow from operations and maintained a 16% gross margin. Net sales decreased 38% to $16.1 million compared to Q2 2024, primarily due to the transition of their largest customer to another supplier.
The company's cash position strengthened to $18.4 million as of June 30, 2025. Despite challenges, Rockwell secured several new product purchase agreements with major healthcare providers, and currently has over 80% of customers under long-term contracts. The company confirmed its 2025 guidance with expected net sales of $65-70 million and adjusted EBITDA between ($0.5M) to $0.5M.
Rockwell Medical (NASDAQ:RMTI), a global healthcare company specializing in hemodialysis products, has scheduled its Q2 2025 earnings release for August 14, 2025. The company will issue a press release at 6:00 AM ET, followed by a conference call and webcast at 8:00 AM ET.
The earnings call will feature presentations from key executives including CEO Mark Strobeck, CFO Jesse Neri, and Chief Commercial Officer Tim Chole, who will discuss the company's financial and operational results for the quarter ended June 30, 2025. A Q&A session will follow the presentation.
Rockwell Medical (Nasdaq: RMTI) and Innovative Renal Care (IRC) have entered into a three-year partnership agreement for hemodialysis products supply. The multi-million dollar agreement includes supply of liquid and dry acid and bicarbonate hemodialysis concentrates, along with the DAMX45 dry acid concentrate mix system.
The partnership aims to enhance IRC's supply chain continuity and streamline workflows across its U.S. dialysis centers. The agreement includes utilization commitments and an option to extend for an additional year. IRC will benefit from reduced storage requirements while maintaining product quality, utilizing Rockwell's CitraPure® and Dri-Sate® dry acid concentrate powders.
Rockwell Medical (NASDAQ: RMTI) reported Q1 2025 financial results, with net sales of $18.9 million, down 17% from $22.7 million in Q1 2024, primarily due to their largest customer transitioning to another supplier. The company maintained gross profit at $3.0 million, with improved gross margin of 16% vs 14% in Q1 2024. Net loss improved 12% to $1.5 million compared to $1.7 million in Q1 2024.
Cash position decreased to $17.3 million from $21.6 million at year-end 2024. The company confirmed its 2025 guidance with expected net sales of $65-70 million, gross margin of 16-18%, and adjusted EBITDA between ($0.5M) to $0.5M. Notable developments include adding a single-use bicarbonate cartridge to their product portfolio and being named a Great Place to Work® for the third consecutive year.
Rockwell Medical (Nasdaq: RMTI), a global healthcare company specializing in hemodialysis products, has scheduled its first quarter 2025 financial results release for Monday, May 12, 2025. The company will issue a press release at 6:00am ET, followed by a live conference call and webcast at 8:00am ET.
The earnings call will feature President and CEO Mark Strobeck, Ph.D., and SVP, CFO Jesse Neri, who will discuss Q1 2025 financial and operational results, followed by a Q&A session. Investors can access the call via phone at (888) 660-6347 (US) or 1 (929) 201-6594 (International) using Conference ID 4944610, or through the webcast at www.RockwellMed.com/Results.
Rockwell Medical (RMTI) reported record financial results for Q4 and full-year 2024, achieving profitability on an adjusted EBITDA basis for the first time. The company generated record net sales of $101.5 million in 2024, up 21% from 2023, and record gross profit of $17.5 million, a 101% increase year-over-year.
Q4 2024 highlights include net sales of $24.7 million (12% increase), gross profit of $3.6 million (27% increase), and adjusted EBITDA of $1.4 million (156% improvement). The company ended 2024 with $21.6 million in cash and equivalents.
However, Rockwell's largest customer will transition to another supplier by mid-2025, potentially resulting in a loss of approximately $34 million in revenue. The company is implementing expense reductions and exploring new opportunities, including the launch of a single-use bicarbonate cartridge targeting a $100 million market opportunity.
Rockwell Medical (RMTI) has announced its participation in DialysisTechConneXion42 (DTX42), scheduled for April 1-4, 2025, in Las Vegas, where they will showcase their hemodialysis concentrates portfolio at Booth #112.
The company's product lineup includes:
- CitraPure®: A citric acid-based, acetate-free concentrate available in liquid and dry powder forms
- Dri-Sate®: An acetic acid-based dry powder concentrate
- RenalPure®: An acetic acid-based liquid concentrate
- SteriLyte®: A liquid bicarbonate concentrate for acute care settings
The company also offers a proprietary Dry Acid Concentrate Mixer, FDA-approved bicarbonate cartridges (720g and 900g), and various ancillary products for hemodialysis providers.
Rockwell Medical (RMTI), a global healthcare company specializing in hemodialysis products, has achieved the 'Great Place to Work' certification for the third consecutive year. The certification highlights the company's success in fostering a high-trust culture with strong employee satisfaction.
According to Lesley Spriggs, VP of Human Resources, the recognition reflects the company's progress in creating a workplace environment that promotes innovation, sustainable performance, and business agility. Employees particularly value attributes such as credibility, respect, fairness, pride, and camaraderie, while finding meaning in their work through the positive impact their hemodialysis products have on patients.
Rockwell Medical (Nasdaq: RMTI), a healthcare company focused on hemodialysis products, has scheduled its Q4 and full-year 2024 financial results release for Thursday, March 20, 2025. The company will issue a press release at 6:00am ET, followed by a live conference call and webcast at 8:00am ET.
The earnings call will feature presentations from key executives including President and CEO Mark Strobeck, Ph.D., CFO Jesse Neri, and Chief Commercial Officer Tim Chole. The discussion will cover financial and operational results, followed by a Q&A session.
Rockwell Medical (RMTI) has entered into a distribution services agreement to add single-use bicarbonate cartridges to its hemodialysis product portfolio. The agreement enables RMTI to distribute 510(k) approved bicarbonate cartridges in two sizes (720g and 900g) to dialysis centers, hospital-based outpatient centers, and skilled nursing facilities.
The single-use bicarbonate disposables market represents an approximate $100 million opportunity and is one of the fastest-growing segments within the hemodialysis concentrates market. The company plans to launch the product in late February 2025, leveraging its existing distribution network and transportation subsidiary.
FAQ
What is the current stock price of Rockwell Med (RMTI)?
What is the market cap of Rockwell Med (RMTI)?
